CDMO excellence in phytocannabinoid products
CB21 Pharma Ltd announces that it entered a global strategic collaboration to combine
its leading expertise and clinical research program in phytocannabinoids with world-class
pharmaceutical strategic consulting and business development services of NorthStar Corporate Finance Ltd and Kru?ger Beteiligungs GmbH, forming a new company called CB21 R&D.
CB21 R&D is a contract development and manufacturing organisation (CDMO) developing treatments for medical pathologies based on standardised refined cannabis extracts produced from cGMP medical cannabis strains, while applying science and principles of evidence-based medicine for final pharmaceutical products. Nonregulated hemp products containing cannabinoids are used by the public for various reasons and are commonly perceived to provide medical benefits, especially regarding pain relief, anxiety, and sleeping disorders. By conducting preclinical and clinical trials, CB21 R&D is focusing on finding conclusive data regarding successful targeting of health concerns using cannabinoids.
R&D network
CB21 R&Ds mission is to help produce pharmaceutical drugs using natural ingredients extracted from the cannabis plants to supplement or substitute chemical pharmaceutical drugs, especially those with harmful side effects including addiction. It partners with the University of Aachen, the University of Freiburg, the University of Olomouc, the University of Brno, Nedcann Severna DOOEL and its shareholder J&K Consulting to support such research. The parent company CB21 Pharma has already successfully developed and registered medical devices and cosmetics using cannabis active ingredients. It is considered one of the most experienced and regulatory advanced EU companies for CBD (Cannabidiol) and other cannabinoids while producing all cannabinoid raw materials in-house, employing EU-GMP Part II compliant processes.
To translate research into practical applications, CB21 R&D has a cooperation agreement with the genetics laboratory at the cultivation centre at Nedcann, a producer of medicinal cannabis dried flowers. Nedcann holds Global GACP and EU-GMP certifications, embodying 33,000 m2 of flowering rooms and laboratory facilities. The founders have archived over 25 years of data from the recreational market in the Netherlands.
Due to the ease of controlling chemical production as opposed to biological production, pharmaceutical companies have been reluctant to invest in medicinal cannabis. The process of cannabinoid pharmaceutical production, from the genetics and growth process to their cultivation and extraction, requires expert guidance and knowledge. It is necessary to provide pharmaceutical companies with consistent and controlled ingredients and processes. CB21 R&D is a CDMO assisting pharmaceutical companies by providing research conclusive data within the phytopharmaceuticals, especially using phytocannabinoids.
